Patents by Inventor Yoshitsugu AOKI

Yoshitsugu AOKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense nucleic acids
    Patent number: 11981894
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: May 14, 2024
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • Antisense nucleic acid inducing skipping of exon 51
    Patent number: 11781140
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: October 10, 2023
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yu Honda, Kaname Muchima, Takahiro Fukui, Saki Hasegawa, Shin'ichi Takeda, Yoshitsugu Aoki
  • Antisense nucleic acid that induces skipping of exon 50
    Patent number: 11655472
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: May 23, 2023
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuta Sunadoi, Reiko Waki, Kaname Muchima, Shin'ichi Takeda, Yoshitsugu Aoki
  • ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51
    Publication number: 20230140736
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 4, 2023
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51
    Publication number: 20230097387
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 30, 2023
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50
    Publication number: 20230073008
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Application
    Filed: December 25, 2020
    Publication date: March 9, 2023
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
    Publication number: 20230045557
    Abstract: The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 9, 2023
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50
    Publication number: 20220333112
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 20, 2022
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE
    Publication number: 20220144902
    Abstract: A method for preparing myotubes in a non-invasive and simple manner and establishes an in vitro test system of an agent used for exon skipping therapy for muscular dystrophy. The method can prepare myotubes from urine-derived cells by introducing the MYOD 1 gene into urine-derived cells and exposing the urine-derived cells to at least one epigenetic regulatory compound.
    Type: Application
    Filed: December 25, 2018
    Publication date: May 12, 2022
    Inventors: Hotake TAKIZAWA, Yoshitsugu AOKI, Shin'ichi TAKEDA, Yukiko ENYA, Yuichiro TONE
  • NUCLEIC ACID DELIVERY COMPLEX
    Publication number: 20220127606
    Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 28, 2022
    Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION
    Inventors: Takashi Okada, Hiromi KINOH, Yoshitsugu AOKI, Shin'ichi TAKEDA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20210147839
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: November 17, 2020
    Publication date: May 20, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Antisense nucleic acids
    Patent number: 10851373
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190040387
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: October 16, 2018
    Publication date: February 7, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Antisense nucleic acids
    Patent number: 10144931
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 4, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180265866
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: September 15, 2016
    Publication date: September 20, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI